A1 Refereed original research article in a scientific journal
A novel three-dimensional template combined with MR-guided(125)I brachytherapy for recurrent glioblastoma
Authors: Xiangmeng He, Ming Liu, Menglong Zhang, Roberto Blanco Sequeiros, Yujun Xu, Ligang Wang, Chao Liu, Qingwen Wang, Kai Zhang, Chengli Li
Publisher: BMC
Publication year: 2020
Journal: Radiation Oncology
Journal name in source: RADIATION ONCOLOGY
Journal acronym: RADIAT ONCOL
Article number: ARTN 146
Volume: 15
Issue: 1
Number of pages: 10
DOI: https://doi.org/10.1186/s13014-020-01586-4
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/48875260
Background: At present, the treatment of recurrent glioblastoma is extremely challenging. In this study, we used a novel three-dimensional non-coplanar template (3DNPT) combined with open MR to guide(125)I seed implantation for recurrent glioblastoma. The aim of this study was to evaluate the feasibility, accuracy, and effectiveness of this technique.
Methods: Twenty-four patients of recurrent glioblastoma underwent 3DNPT with open MR-guided(125)I brachytherapy from August 2017 to January 2019. Preoperative treatment plan and 3DNPT were made according to enhanced isovoxel T1-weighted MR images. I-125 seeds were implanted using 3DNPT and 1.0-T open MR imaging guidance. Dosimetry verification was performed after brachytherapy based on postoperative CT/MR fusion images. Preoperative and postoperative dosimetry parameters of D90, V100, V200, conformity index (CI), external index (EI) were compared. The objective response rate (ORR) at 6 months and 1-year survival rate were calculated. Median overall survival (OS) measured from the date of brachytherapy was estimated by Kaplan-Meier method.
Results: There were no significant differences between preoperative and postoperative dosimetry parameters of D90, V100, V200, CI, EI (P > 0.05). The ORR at 6 months was 75.0%. The 1-year survival rate was 58.3%. Median OS was 12.9 months. One case of small amount of epidural hemorrhage occurred during the procedure. There were 3 cases of symptomatic brain edema after brachytherapy treatment, including grade three toxicity in 1 case and grade two toxicity in 2 cases. The three patients were treated with corticosteroid for 2 to 4 weeks. The clinical symptoms related to brain edema were significantly alleviated thereafter.
Conclusions: 3DNPT combined with open MR-guided(125)I brachytherapy for circumscribed recurrent glioblastoma is feasible, effective, and with low risk of complications. Postoperative dosimetry matched the preoperative treatment plan. The described method can be used as a novel implantation technique for(125)I brachytherapy in the treatment of recurrent gliomas.
Downloadable publication This is an electronic reprint of the original article. |  |
